|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.05 EUR | -0.33% |
|
-2.87% | -34.69% |
| Mar. 18 | Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development | MT |
| Mar. 18 | Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG | CI |
On March 5, 2020, Biotalys NV closed the transaction. The company has amended the terms of the transaction. The company has received €45,000,000 in the transaction.
On the same date, the company has received €10,000,000 in its second tranche. The second tranche included participation from current shareholders and new investor Novalis LifeSciences Investments LLC. As a part of the transaction, Marijn Dekkers from Novalis LifeSciences Investments LLC, will join the company's board of directors.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 159.8 EUR | -0.37% | +2.24% | 5.61B | ||
| 44.5 EUR | -1.22% | +0.23% | 1.34B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -34.69% | 105M | |
| +1.34% | 7.35B | |
| +8.19% | 3.18B | |
| +11.42% | 862M | |
| -4.02% | 355M | |
| +19.77% | 313M |
BIOTALYS NV 
